RORA and Autoimmunity: Our current study, by identifying RORα as a key regulator of the sustained Th17 effector program, suggests that targeting this receptor could be a viable strategy for treating autoimmune pathologies linked to Th17 effector functions in chronically inflamed patient tissues.